-
5 days ago | 
benzinga.com | Vandana Singh
On Thursday, U.S. Food and Drug Administration (FDA) Commissioner Martin A. Makary announced an aggressive timeline to scale the use of artificial intelligence (AI) internally across all FDA centers by June 30, following the completion of a new generative AI pilot for scientific reviewers. Makary has directed all FDA centers to begin deployment immediately, with the goal of full integration by the end of June.
-
5 days ago | 
benzinga.com | Vandana Singh
In March, the U.S. Department of Health and Human Services (HHS) unveiled a sweeping restructuring plan to cut costs, streamline operations, and refocus priorities. Congress has long considered HHS vital to national well-being, appropriating $2.5 trillion for Fiscal Year 2024 to support its broad mandate across medicine, public health and social services.
-
5 days ago | 
benzinga.com | Vandana Singh
In March, the U.S. Department of Health and Human Services (HHS) unveiled a sweeping restructuring plan to cut costs, streamline operations, and refocus priorities. Congress has long considered HHS vital to national well-being, appropriating $2.5 trillion for Fiscal Year 2024 to support its broad mandate across medicine, public health and social services.
-
6 days ago | 
benzinga.com | Vandana Singh
Local governments across the U.S. are suing the Trump administration over what they allege is an unlawful termination of more than $11 billion in public health grants. What Happened: In March, the Centers for Disease Control and Prevention said it is withdrawing $11.4 billion in funds allocated to state and community health departments, nongovernment organizations, and international recipients in response to the pandemic.
-
6 days ago | 
benzinga.com | Vandana Singh
Corvus Pharmaceuticals, Inc. CRVS on Thursday released new interim data from the Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The data demonstrated a favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 (200 mg twice per day, total daily dose 400 mg) compared to cohorts 1 and 2 (100 mg twice per day and 200 mg once per day, total daily dose 200 mg).
-
6 days ago | 
benzinga.com | Vandana Singh
ANI Pharmaceuticals Inc ANIP reported first-quarter adjusted earnings of $1.70 per share on Friday, up from $1.21 a year ago, beating the consensus of $1.38 per share. The company reported sales of $197.12 million, up 43.4% year over year, beating the consensus of $180.68 million. On an organic basis, excluding the acquisition of Alimera, total net revenues grew 31.7% year-over-year.
-
6 days ago | 
benzinga.com | Vandana Singh
Protagonist Therapeutics Inc. PTGX, in collaboration with Johnson & Johnson JNJ, released new clinical data from the Phase 3 ICONIC-TOTAL study investigating icotrokinra for scalp and genital psoriasis. • At week 16, 57% of patients treated with once daily icotrokinra achieved the study’s primary endpoint with an Investigator’s Global Assessment (IGA) b score of 0/1 (clear or almost clear skin) and a ≥2-grade improvement from baseline at Week 16 compared to 6% of patients receiving placebo.
-
6 days ago | 
benzinga.com | Vandana Singh
Embecta Corp. EMBC posted on Friday the second-quarter 2025 adjusted earnings of 70 cents per share, up from 67 cents a year ago, beating the consensus of 53 cents. The diabetes care company reported sales of $259 million, beating the consensus of $253.94 million. Revenues were down 9.8% on a reported basis, down 7.7% on an adjusted constant currency basis. U.S. revenues decreased 8.4% on both a reported and adjusted constant currency basis.
-
6 days ago | 
benzinga.com | Vandana Singh
Insulet Corporation PODD reported first-quarter adjusted earnings of $1.02 per share, beating the consensus of 80 cents. The automated insulin delivery technology maker reported sales of $569 million, up 28.8% year over year (29.8% in constant currency), beating the consensus of $543.4 million, exceeding the high end of the company’s guidance range of 25% in constant currency. • Total Omnipod revenue reached $554.1 million, an increase of 28.0%, or 29.0% in constant currency.
-
6 days ago | 
benzinga.com | Vandana Singh
Viatris Inc. VTRS on Thursday, released data from Phase 3 study evaluating the contraceptive efficacy and safety of XULANE LO low dose weekly dermal patch of 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per day in women of childbearing potential. In this study, XULANE LO demonstrated a favorable efficacy and safety profile; no new safety concerns were identified. The study demonstrated contraceptive efficacy with a Pearl Index (PI) of 4.14.
